Comparative Effectiveness of Tildrakizumab 200 Mg Versus Tildrakizumab 100 Mg in Psoriatic Patients with High Disease Burden or above 90 Kg of Body Weight: a 16-Week Multicenter Retrospective Study – IL PSO (italian Landscape Psoriasis) Luigi Gargiulo , Luciano Ibba , Ruggero Cascio Ingurgio , Piergiorgio Malagoli , Fabrizio Amoruso , Anna Balato , Federico Bardazzi , Pina Brianti , Giovanna Brunasso , Martina Burlando , Anna E. Cagni , Marzia Caproni , Carlo G. Carrera , Andrea Carugno , Francesco Caudullo , Aldo Cuccia , Paolo Dapavo , Eugenia V. Di Brizzi , Valentina Dini , Francesca M. Gaiani , Paolo Gisondi , Claudio Guarneri , Claudia Lasagni , Gaetano Licata , Francesco Loconsole , Angelo V. Marzano , Matteo Megna , Santo R. Mercuri , Maria L. Musumeci , Diego Orsini , Simone Ribero , Valentina Ruffo Di Calabria , Francesca Satolli , Davide Strippoli , Massimo Travaglini , Emanuele Trovato , Marina Venturini , Leonardo Zichichi , Mario Valenti , Antonio Costanzo , Alessandra Narcisi JOURNAL OF DERMATOLOGICAL TREATMENT（2024）
Key words
Biologics, psoriasis, psoriasis treatment, tildrakizumab
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
